Thermo Fisher - Vasculitis Portfolio

28Apr

Thermo Fisher – Vasculitis Portfolio

Last updated: 28th April, 2025

ANCA-associated diseases are caused by vasculitis of the small vessels in which antineutrophil cytoplasmic antibodies (ANCA) can be detected in a patient’s blood.^1,2 A rapid diagnosis of ANCA-associated small-vessel vasculitis is critically important because life-threatening injury to organs often develops quickly and can be rapidly mitigated by immunosuppressive therapy.²

The group of antineutrophil cytoplasmic autoantibody ANCA-associated vasculitides (AAVs) comprises microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA).³

All of these diseases show features of vasculitis of the small vessels, but otherwise affect various different target organs with varying ANCA positivity.³ During the active stage of the disease, ANCAs against myeloperoxidase (MPO) and/or proteinase 3 (PR3) can be detected in MPA and GPA patients.^2,3 Among patients with EGPA, less than 50% have ANCAs; the presence of ANCAs is associated with the typical manifestations of small vessel vasculitis, such as glomerulonephritis.^1,3 Taking the concentrations of antibodies into account improves clinical interpretation.⁴Literature suggests the potential to use ANCAs for the monitoring of relapse and remission states of already diagnosed patients.^5,6

Advantages of routine testing with EliA PR3^s and EliA MPO^s:

For the laboratory
- Improved efficiency with reliable results benefitting both clinicians and patients.²
For the healthcare system
- Clear results the ﬁrst time, reducing the need for re-testing and enabling earlier diagnoses and more cost-effective treatments for patients.

For the clinician
- Increased conﬁdence in management of patients with ANCA-associated vasculitis.
- Greater ease of differentiation between ANCA-associated vasculitis and other renal diseases or other ANCA-positive, non-vasculitic diseases.
For the patient
- Improved quality of life due to quicker diagnosis and faster treatment.

View the Thermo Fisher Vasculitis Portfolio Brochure

Download >

References:

Moiseev S, Bossuyt X, Arimura Y, Blockmans D, Csernok E, Damoiseaux J, et al. European EGPA Study Group. International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. Am J Respir Crit Care Med 2020 Jun.
de Joode AA, Roozendaal C, van der Leij MJ, Bungener LB, Sanders JS, Stegeman CA. Performance of two strategies for urgent ANCA and anti-GBM analysis in vasculitis. Eur J Intern Med. 2014 Feb;25(2):182–186.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1–11.
Damoiseaux J. ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization. Front Immunol. 2021 Mar;12:656796.
Segelmark M, Phillips BD, Hogan SL, Falk RJ, Jennette JC. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin Diagn Lab Immunol. 2003 Sep;10(5):769–774.
Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int. 2003 Mar;63(3):1079-8.

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.

Request a Quote

Request Quote